Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
A user's experience with hair loss treatments, specifically Minoxidil and finasteride, which they have used without side effects for a year. Other users shared their experiences and advice about potential side effects and supplements to help.